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Chronic hypoxia causes pulmonary hypertension (PH), vascular
remodeling, right ventricular (RV) hypertrophy, and cardiac failure.
Protein kinase G Iα (PKGIα) is susceptible to oxidation, forming an
interprotein disulfide homodimer associated with kinase targeting
involved in vasodilation. Here we report increased disulfide PKGIα
in pulmonary arteries from mice with hypoxic PH or lungs from
patients with pulmonary arterial hypertension. This oxidation is
likely caused by oxidants derived from NADPH oxidase-4, super-
oxide dismutase 3, and cystathionine γ-lyase, enzymes that were
concomitantly increased in these samples. Indeed, products that
may arise from these enzymes, including hydrogen peroxide, glu-
tathione disulfide, and protein-bound persulfides, were increased
in the plasma of hypoxic mice. Furthermore, low-molecular-weight
hydropersulfides, which can serve as “superreductants” were at-
tenuated in hypoxic tissues, consistent with systemic oxidative
stress and the oxidation of PKGIα observed. Inhibiting cystathio-
nine γ-lyase resulted in decreased hypoxia-induced disulfide PKGIα
and more severe PH phenotype in wild-type mice, but not in
Cys42Ser PKGIα knock-in (KI) mice that are resistant to oxidation.
In addition, KI mice also developed potentiated PH during hypoxia
alone. Thus, oxidation of PKGIα is an adaptive mechanism that limits
PH, a concept further supported by polysulfide treatment abrogat-
ing hypoxia-induced RV hypertrophy in wild-type, but not in the KI,
mice. Unbiased transcriptomic analysis of hypoxic lungs before
structural remodeling identified up-regulation of endothelial-to-
mesenchymal transition pathways in the KI compared with wild-
type mice. Thus, disulfide PKGIα is an intrinsic adaptive mechanism
that attenuates PH progression not only by promoting vasodilation
but also by limiting maladaptive growth and fibrosis signaling.
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Hypoxic pulmonary vasoconstriction is a physiological re-sponse that enhances blood oxygenation during localized
alveolar hypoxia. When larger territories become hypoxic, as
occurs with high-altitude living or with lung disease, this pro-
motes sustained pulmonary hypertension (PH) and vascular
remodeling involving right ventricular (RV) hypertrophy, car-
diac failure, and premature death (1–3). Prolonged hypoxia is
associated with production of oxidants (3, 4), which historically
have been considered pathogenic. However, oxidants can par-
ticipate in regulatory and adaptive redox signaling by reversible
modification of proteins (5–7). PKG is a serine/threonine pro-
tein kinase, which phosphorylates biologically important targets,
including those that regulate smooth muscle relaxation, platelet
function, and cell growth and division. PKGIα is susceptible to
oxidation, forming an interprotein disulfide homodimer associated
with kinase targeting and activation resulting in vasodilation and
cardiac diastolic relaxation (8–10). During acute hypoxia, pulmo-
nary cells become proreducing, which may explain the conversion of
disulfide PKGIα to its reduced form under such conditions (11) and
so its potential contribution to hypoxic pulmonary vasoconstriction.
In contrast, chronic hypoxia, a time when production of reactive
oxygen species (ROS) is elevated (4, 12–15), is paradoxically asso-
ciated with increased PKGI expression (16), arguably serving an
adaptive mechanism to limit PH. Consistent with up-regulation of
the kinase being adaptive, PKGI knock-out mice develop sponta-
neous PH even during normoxia (17). In addition, PKGIα over-
expression reduces migration of pulmonary arterial smooth muscle
cells (PASMCs) subjected to hypoxia in vitro (18), suggesting a
potential therapeutic value for PKGIα in hypoxia-associated pul-
monary arterial remodeling.
Posttranslational regulation of PKG has recently emerged as a
topic of interest in PH. Decreased PKG activity due to tyrosine
nitration has been reported (19), with this nitrative stress-
mediated PKG dysfunction being associated with poorer out-
comes in caveolin 1-deficient mice during PH (19). A role for
disulfide PKGIα in the acute vascular responses to hypoxia has
been suggested (11); however, the occurrence and role of this
oxidative modification during sustained low levels of oxygen re-
main to be elucidated. Although oxidants have been proposed as
mediators of the adverse vascular remodeling that accompanies
PH (20–22), of course this mirrors a generic paradigm proposed
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for most diseases. This has led to antioxidant supplements being
advocated as a panacea, as they have for PH (13, 23), but, in
general, they have failed in large-scale clinical trials and often
have proven harmful when administered to humans with various
diseases (24, 25). This may be because antioxidants prevent in-
trinsic cellular responses (25, 26), for example by neutralizing
ROS species that may otherwise react with redox sensor pro-
teins, such as PKGIα, to initiate adaptive signaling.
The role of redox-regulated PKGIα in controlling the tone of
systemic vessels has been widely reported (8–10), whereas the
importance of these events in the pulmonary circulation is less
well defined. In the present study, the redox state of pulmonary
PKGIα and its potential role in the pathogenesis of hypoxia-
induced PH was investigated. The novelty of this study is that
disulfide PKGIα accumulates during chronic hypoxia and that
this serves an endogenous, adaptive redox mechanism by
promoting vasodilation that limits PH and the associated
adverse pulmonary arterial and right heart remodeling that
otherwise ensues. Furthermore, disulfide PKGIα accumula-
tion during chronic hypoxia was associated, likely causatively,
with a loss of low-molecular-weight hydropersulfides that can
serve as “superreductants” that otherwise maintain the kinase
in the reduced state. Pharmacological agents that induce
disulfide PKGIα have therapeutic potential in PH, another
original finding of this work.
Results and Discussion
Disulfide PKGIα Level Is Elevated in Pulmonary Tissues from Hypoxic
Mice and Lungs from Pulmonary Hypertensive Patients. Mouse
models of hypoxic PH reproduce the pulmonary vessel con-
striction and muscularization (27, 28), observed in humans in
Group 3 of the World Health Organization PH classification
system (3, 29). For this reason, we established and validated this
PH model in C57BL/6 mice by subjecting them to chronic hyp-
oxia (10% O2) for 28 d (SI Appendix, Fig. S1 A–D). Sub-
sequently, wild-type (WT) alone, or WT together with “redox-
dead” Cys42Ser PKGIα knock-in (KI) mice that cannot form
PKGIα disulfide dimer (8, 10) were compared in their responses
to 3, 14, or 28 d of hypoxia; 3 or 14 d of hypoxia increased the
amount of total, as well as disulfide, PKGIα in WT pulmonary
vessels compared with those maintained in normoxic room air
(Fig. 1 A and B). Similarly, elevated disulfide PKGIα levels, as
well as a trend toward increased total PKGIα, were evident in
whole lungs of mice subjected to hypoxia for 28 d (Fig. 1C), or
those from human pulmonary arterial hypertension (PAH) pa-
tients (Fig. 1D). This elevation in total PKGI expression was as
observed by others (16), and was considered an adaptive process.
However, it was unclear whether the increase in disulfide PKGIα
contributes to pulmonary adaptation to hypoxia. PKGIα oxida-
tion was not altered in the RV and was slightly reduced in the left
ventricle and septum of hypoxic WT mice (SI Appendix, Fig.
S2A). As anticipated, disulfide PKGIα was not evident in tissues
from the KI mice regardless of the experimental intervention
(Fig. 1 B and C and SI Appendix, Fig. S2A), although total
PKGI was up-regulated in pulmonary vessels (Fig. 1 A and B)
and lungs (Fig. 1C) of the KI mice in response to hypoxia, as
occurred in WTs.
Next, we went on to investigate the molecular basis for pul-
monary PKGIα oxidation during chronic hypoxia. Our attention
turned to the ROS that might mediate oxidation of PKGIα, and
their potential enzymatic sources. Previous studies showed that
hydrogen peroxide (H2O2) (8, 30), persulfides (9), or nitric
oxide-related species (10) induced oxidation of PKGIα. In ad-
dition, expression of the H2O2-producing superoxide dismutase
(SOD) enzyme was altered in hypoxic PH (12, 31). The H2O2-
generating enzyme nonphagocytic NADPH oxidase-4 (Nox4),
that can also increase cystathionine γ-lyase (CSE) (32), was up-
regulated in pulmonary vascular cells and pulmonary vessels
during chronic hypoxia in vitro (33) and in vivo (20). For these
reasons, expression of SOD, Nox4, and CSE enzymes was com-
pared in normoxic or hypoxic tissues. Hypoxia increased Nox4,
SOD3, and CSE protein expression comparably in WT or KI
pulmonary arteries (Fig. 1 A and B) and lungs (Fig. 1C).
SOD1 or SOD2 expression was not significantly altered in the
lungs of mice subjected to hypoxia (SI Appendix, Fig. S2B), al-
though the latter was previously observed to decrease in PH
lungs (34, 35). To ensure accurate measurement of Nox4 protein
expression, the custom-made Nox4 antibodies were validated by
using Nox4-knockout lung tissue (SI Appendix, Fig. S2C).
Up-regulation of oxidant-producing proteins may reflect an
adaptive role for oxidants whereby they lower pulmonary blood
pressure by disulfide PKGIα-dependent vasodilation. Indeed,
increased SOD3 expression is consistent with an established role
for this enzyme in protecting the lung from hypoxia-induced PH
(36–38). Consistent with such a protective role for the dismutase,
SOD3 depletion from smooth muscle cells potentiated the se-
verity of phenotypic responses to PH in mice (39), whereas its
overexpression in lung attenuated PH-induced arterial remod-
eling and pressure (37). Thus, the increased SOD3 observed
herein was likely an adaptive response that limits dysfunction
during PH, with the rational likelihood that the increased
Nox4 that also generates H2O2 is likewise beneficial. In line with
this, Fawn-Hooded rats that produce less H2O2 develop spon-
taneous PH, compared with Sprague Dawley controls. However,
treatment of Fawn-Hooded rats with an SOD2 mimetic, which is
anticipated to enhance H2O2 derived from superoxide, abro-
gated the PH phenotype (27), consistent with a crucial role for
oxidants in the regulation of pulmonary vasotone.
Nox4 up-regulation during PH has been observed multiply at
both the messenger RNA (mRNA) and protein levels (4, 20, 21, 33,
40), but little is known about the downstream targets of the H2O2
generated by this enzyme (21). A large body of literature describes
detrimental effects of Nox4 in PH (21, 22, 41, 42). For example,
inhibition of Nox4 by VCC588646, VCC202273, or GKT136901
reduced PASMC proliferation in vitro, and vascular remodeling
together with RV hypertrophy in monocrotaline-treated rats (22),
consistent with a causative role for Nox4 in PH. However, the
specificity and isoform selectivity for many of these inhibitors have
been questioned (43), and thus the protection observed may result
from a widespread inhibition of superoxide-producing Nox iso-
forms, rather than Nox4 alone. Indeed, a recent report demon-
strated that constitutive or inducible Nox4 knock-out mice develop
a similar PH phenotype to WTs when subjected to chronic hypoxia
for 21 d (44). Therefore, Nox4 up-regulation may serve as a pro-
tective rather than a detrimental mechanism. Nox4-mediated cys-
teine oxidation of KV1.5 channels leads to the inhibition of the
channel activity, sustained depolarization, and pulmonary vaso-
constriction observed during the pathogenesis of hypoxia-induced
PH (21). In contrast, another group showed that KV1.5 oxidation
induces activation of these channels, which couples to vasodilation
(rather than vasoconstriction) in response to H2O2 (45). Oxidants
also induce disulfide PKGIα (8, 10, 30), which significantly mediates
vasodilation by H2O2, including via phosphoactivation of large-
conductance potassium channels (46). It is likely that chronic hyp-
oxia results in oxidation of multiple other proteins, but studying the
“redox-dead” PKGI KI allowed a specific role for oxidation of this
kinase in adaptation to PH to be defined (7, 47).
The expression of CSE enzyme was also increased during
hypoxia. CSE is known for its generation of the vasorelaxant H2S
(48), while this enzyme may also directly generate cysteine per-
sulfides from cystine (49). The term “persulfide” is defined here
as all molecular species containing more than one sulfur atom in
each low-molecular-weight and protein/peptidyl thiol moiety.
H2S can additionally be oxidized to the persulfides by the
product of SOD3 and Nox4, namely H2O2 (9, 50), or directly by
Cu/Zn SOD (51). These persulfide species cause vasodilation
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and blood pressure lowering by promoting disulfide PKGIα (9).
Thus, the increased expression of SOD3, Nox4, and CSE would
provide an integrated mechanism that limits dysfunction during
PH by generating oxidant species that couple to vasodilation by
increasing disulfide PKGIα. Such vasodilation would reduce
pulmonary and RV pressure to limit the progressive adverse
remodeling, consistent with the disease-limiting effects of ther-
apies that enhance cGMP-dependent activation of PKGI (52–
54). Therefore, protein oxidation, as observed in idiopathic PAH
(55), may provide beneficial, adaptive mechanisms, as opposed
to the solely deleterious role it has historically been associated
with. It is notable that the increased disulfide PKGIα, as well as
the Nox4 and CSE enzymes that likely contribute to oxidation of
the kinase, are observed in samples from humans with PAH
(Fig. 1D).
Alteration of Reactive Oxygen and Sulfur Species Metabolome During
Chronic Hypoxia. To further explore the molecular nature of the
species that mediate PKGIα oxidation, reactive oxygen and sul-
fur metabolites were analyzed in lungs or plasma of mice sub-
jected to chronic hypoxia for 3 and 14 d. Hypoxia increased
pulmonary disulfide PKGIα levels (Fig. 2A), substantiating the
observations shown in Fig. 1. A one-step fluorescence-based
Amplex Red assay was employed to assess H2O2 abundance in
these samples, as it is a product of both Nox4 and SOD3. We
observed a time-dependent increase of H2O2 in lungs of mice
Fig. 1. Disulfide PKGIα is increased in pulmonary arteries and lungs of mice subjected to chronic hypoxia and in lungs of PAH patients. (A) Disulfide PKGIα,
total PKGI, CSE, Nox4, and SOD3 protein expression in vessels of WT mice subjected to either normoxia or chronic hypoxia for 3 d. (B) Disulfide PKGIα, total
PKGI, CSE, Nox4, and SOD3 protein expression in vessels of WT or Cys42Ser PKGIα KI mice subjected to either normoxia or chronic hypoxia for 14 d. (C)
Disulfide PKGIα, total PKGI, CSE, Nox4, and SOD3 protein expression in lungs of WT or Cys42Ser PKGIα KI mice subjected to either normoxia or chronic hypoxia
for 28 d. (D) Disulfide PKGIα, total PKGI, CSE, and Nox4 protein expression in lungs of PAH patients. *P < 0.05, **P < 0.01 versus normoxia or respective WT;
n = 6 to 8 per group; monomer, PKGIα monomer; dimer, PKGIα dimer; Nox4, NADPH oxidase 4; SOD, extracellular SOD; WT, WT mice; PKG KI, “redox-dead”
Cys42Ser PKGIα KI mice. In some cases, the aspect ratio of the original immunoblots was altered to enable a concise multipanel figure with a consistent
presentation style; the original uncropped representative images of these immunoblots are also available in SI Appendix, Figs. S8 and S9.











subjected to hypoxia, whereas plasma H2O2 was only elevated after
3 d (Fig. 2A). This was anticipated and rationalized by the concomi-
tantly increased Nox4 and SOD3 expression in pulmonary arteries
after 3 d or 14 d of hypoxia (Fig. 1 A and B). The ROS-generating
activity of Nox4 is regulated primarily by its expression (56–58); in
addition, both mRNA and protein levels of Nox4 can be up-regulated
via hypoxia-inducible factor 1α (33). Therefore, it is likely that H2O2
elevation in hypoxic lungs is, at least partially, a result of increased
protein abundance and activity of this oxidase. Overall, the elevated
amounts of H2O2 observed in hypoxic tissues are consistent with in-
creased expression and activity of both Nox4 and SOD3, but other
ROS-producing enzymes may also contribute.
Fig. 2. Reactive oxygen and sulfur species level in lung and plasma of mice subjected to chronic hypoxia. (A) Representative disulfide PKGIα increase in lungs
ofWTmice subjected to either normoxia or chronic hypoxia for 3 and 14 d. (B) Low-molecular-weight persulfides and oxidized forms of sulfur metabolism in lung and
plasma of WTmice subjected to either normoxia or chronic hypoxia for 3 and 14 d. Thiol and hydropersulfide-containing compound were alkylated with tyrosine and
a hydroxyphenyl-containing derivative, β-(4-hydroxyphenyl)ethyl iodoacetamide (HPE-IAM), and their HPE-IAM adducts were quantified by liquid chromatography-
electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). (C) Protein persulfidation in lung and plasma of WT mice subjected to either normoxia or chronic
hypoxia for 3 and 14 d. Protein-bound hydropersulfides were alkylated with HPE-IAM, and pronase digest samples were quantitatively analyzed by LC-ESI-MS/MS. *P <
0.05, **P < 0.01 versus normoxia; n = 6 to 8 per group. In some cases, the aspect ratio of the original immunoblots was altered to enable a concise multipanel figure
with a consistent presentation style; the original uncropped representative images of these immunoblots are also available in SI Appendix, Fig. S10.
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Next, the sulfur metabolites were analyzed by mass spec-
trometry, as before (49, 59). Hypoxia induced a time-dependent
reduction in plasma homocysteine (Fig. 2A), which may reflect the
increased expression and activity of pulmonary CSE, consuming
this as a substrate. Another H2S producing enzyme, namely cys-
tathionine β-synthase, can also metabolize homocysteine (60);
however, we could not detect this protein in the lung. Reactive
sulfur intermediates, such as low-molecular-weight persulfides
(RSnH and RSSnR, n > 1), as well as total protein persulfidation
were assessed (Fig. 2 B and C and SI Appendix, Fig. S3). These
sulfur intermediates have inherent chemical properties that confer
reactivity to different biological targets (49, 59), and are antici-
pated to alter the thiol redox state of proteins, including PKGIα.
Cysteine (CysSSH) and glutathione persulfides (GSSH) were
time-dependently decreased in both lungs and plasma, although
the change in GSSH levels failed to reach statistical significance in
plasma (Fig. 2B). This is notable, as these hydropersulfide species
are superior reductants that are capable of rapid neutralizing re-
actions with ROS, as well as the reduction of disulfide-containing
molecules (49, 61), including those on PKGI. Other sulfur deriv-
atives such as HS−, HSS−, and thiosulfates (HS2O3
−) were also
decreased in the plasma and lung in hypoxia (SI Appendix, Fig.
S3). Reduction of such reducing equivalents will favor accumu-
lation of oxidized products, and is consistent with the increased
disulfide PKGIα present in the pulmonary system during hypoxia.
It was notable that lung cystine was decreased in a time-dependent
manner during hypoxia, while its plasma level was hardly detect-
able at 14 d of hypoxia, after a transient increase at 3 d (Fig. 2B).
Cystine is an alternative substrate for CSE that can be utilized by
this enzyme specifically during oxidative stress (49). Therefore,
these data further corroborate an increase in systemic CSE ac-
tivity, and are consistent with increased oxidative stress and higher
amounts of disulfide PKGIα during hypoxia.
Thus, the abundance of some reactive sulfur species is attenuated
in hypoxia-induced PH. Interestingly, a decrease in reactive persul-
fide species accompanied by increased CSE expression was recently
reported in the lungs of patients with chronic obstructive pulmonary
disease (62). Such lower amounts of hydropersulfides may appear
counterintuitive to increased CSE activity (61). A likely explanation
of this is that the sulfur species produced by CSE are eliminated by
H2O2 or other endogenous electrophiles accumulating in the hyp-
oxic tissue. Indeed, oxidized glutathione was increased in plasma
(Fig. 2B), while no increase in plasma H2O2 was observed after 14 d
of hypoxic exposure (Fig. 2A), further supporting this suggestion.
Furthermore, protein-bound persulfides (CysSSH/CysSH) were in-
creased in plasma after 14 d of hypoxia (Fig. 2C). Enhanced protein
persulfidation in plasma may represent a compensatory induction of
persulfide biosynthesis in response to the sulfide consumption dur-
ing hypoxia. Although the exact underlying mechanisms still remain
unclear, these observations are consistent with systemic oxidative
stress, including within the pulmonary system.
Effect of CSE Inhibition and Polysulfide Donors on Hypoxia-Induced
PH. To experimentally test the importance of CSE in limiting PH
during chronic hypoxia, C57BL/6 mice were subjected to chronic
hypoxia for 14 d with or without L-propargylglycine (L-PPG)—a
pharmacological inhibitor of this enzyme; 14 d of hypoxia, albeit
not when L-PPG was also present, increased pulmonary disulfide
PKGIα levels compared with normoxia (Fig. 3A). Moreover, L-
PPG treatment of mice subjected to hypoxia increased RV
pressure and hypertrophy compared with vehicle-treated hypoxic
mice (Fig. 3A). CSE expression was decreased in WT or KI mice
by administering small interfering RNA (siRNA) to them in vivo.
This silencing approach, which was initially validated in mouse
PASMCs (SI Appendix, Fig. S4A), decreased lung CSE protein
by nearly 50%, with a trend toward decreased disulfide PKGIα in
the same samples (Fig. 3B). As with inhibition of CSE by L-PPG,
siRNA-induced knockdown of this enzyme increased RV pres-
sure and hypertrophy in WT mice compared with vehicle-treated
controls subjected to normoxia or hypoxia (Fig. 3B). There was
no effect of CSE siRNA on RV systolic pressure (RVSP) or RV
hypertrophic remodeling in the KI mice (SI Appendix, Fig. S4B).
These observations are consistent with the causal role of CSE-
derived persulfide species that facilitate disulfide PKGIα and
limit PH and the consequent dysfunction.
To test this concept further, mice were exposed to potassium
polysulfides (persulfides) or sodium hydrosulfide, interventions
that previously induced disulfide PKGIα (9). Once again, po-
tassium polysulfide induced PKGIα oxidation, this time in hu-
man PASMCs (Fig. 3C), and either compound limited RV
pressure increases and hypertrophy in C57BL/6 mice subjected
to hypoxia (Fig. 3D and SI Appendix, Fig. S4C), consistent with
its vasodilatory role. Notably, the protection provided to WT
mice by polysulfides was less evident in the KI mice (Fig. 3D),
further strengthening the rationale that disulfide PKGIα for-
mation in the lung during hypoxia serves as a protective mech-
anism. These observations strike a chord with the inverse
correlation between plasma H2S level and pulmonary arterial
pressure observed in humans with PAH (63).
“Redox-Dead” Cys42Ser PKGIα KI Mice Develop More Severe
Hypoxia-Induced PH Phenotype. The role of disulfide PKGIα as
an adaptive mechanism during hypoxic PH was examined in
more depth by comparing disease progression in WT versus KI
mice. KI mice showed potentiated increases in RV hypertrophy
and pressure (Fig. 4 A and B) compared with WT during hyp-
oxia. This potentiated dysfunction in the KIs that cannot form
the targeting and activating disulfide PKGIα during hypoxia was
further evidenced by an exacerbated decline in pulmonary vas-
cular blood flow indexes, together with a higher pulmonary
vascular resistance (PVR) (Fig. 4C). Cardiac function decline
was moderate in both genotypes (SI Appendix, Fig. S5).
Phosphorylation of vasodilator-stimulated phosphoprotein
(VASP) was decreased, while myosin light chain (MLC)
phosphorylation was increased in lungs (Fig. 4D) and pul-
monary arteries (SI Appendix, Fig. S6A) of the KI compared
with WT during hypoxia. Lack of VASP phosphorylation in
the KIs is consistent with deficient disulfide PKGIα targeting,
and was observed previously (10). Phosphorylated MLC status
is modulated by MLC kinase and by MLC phosphatase, the
activity of which is phosphoregulated by PKGIα (64, 65).
Disulfide PKGIα is anticipated to activate MLC phosphatase
which, in turn, dephosphorylates MLC and enables smooth muscle
relaxation (64). The Cys42Ser PKGIα KIs are likely deficient in this
activity, resulting in higher MLC phosphorylation. This may be
consistent with Cys42 oxidation targeting PKGIα, which is plausi-
ble given the disulfide occurs in the middle of the N-terminal
leucine zipper of the kinase that binds a similar zipper in MLC
phosphatase (47, 64). The enhanced phosphorylation of MLC
in the KI during hypoxia is in agreement with enhanced vas-
oconstrictory kinase activation (66, 67), with an inability to
suitably activate the disulfide PKGIα-dependent activation of
MLC phosphatase that enables compensatory vasodilation
in WT.
H2O2-dependent Vasodilation Is Impaired in “Redox-Dead” Cys42Ser
PKGIα KI Pulmonary Arteries. Disulfide PKGIα contributes to
blood pressure homeostasis, being a component of endothelium-
derived hyperpolarizing factor-dependent vasodilation (8, 47). It
decreases calcium concentration in vascular smooth muscle cell,
and mediates oxidant-induced vasodilation (68). Since PASMCs
are abundant in PKGIα and its disulfide-dimerized form, it was
rational to test whether this mechanism is preserved in pulmo-
nary vessels. First- or second-order pulmonary arteries from the
KIs demonstrated impaired vasodilatory responses to H2O2
compared with the WT, despite equal constriction to the pressor











agonist U-46619 in each genotype (SI Appendix, Fig. S6B). Iso-
lated perfused mouse lung was next employed to test vascular
responses in pulmonary resistance vessels. Potentiated pressor
agonist-induced constriction and deficient pulmonary vaso-
dilatory responses to H2O2 were observed in the perfused lungs
from the KI mice, compared with the WT (SI Appendix, Fig.
S6C), further supporting the crucial vasodilatory role of disulfide
PKGIα in pulmonary circulation. This is consistent with a global
role for PKGIα oxidation in vasodilation (8, 11).
Disulfide PKGIα formation transduces increased abundance
of oxidants to vasodilation in the systemic circulation (8, 10),
with the same basic events clearly in operation in the pul-
monary system. This oxidative activation of PKGIα occurs in
the pulmonary tissues of WT mice during chronic hypoxia for
28 d, and the evidence presented thus far indicates this off-
sets the hypertension in airway blood vessels that occurs at
this time. This adaptive mechanism that enhances PKGIα
activity to trigger vasodilation lowers RV pressure, thus re-
ducing the associated RV hypertrophic remodeling. It is
plausible that interventions that increase disulfide PKGIα
may be therapeutic, limiting progression to heart failure in
PAH patients.
Fig. 3. Effect of CSE inhibition and polysulfides in hypoxia-induced PH. (A) Pulmonary disulfide PKGIα expression, RV pressure, and RV to left ventricle +
septum (LV+S) ratio in C57BL/6 mice subjected to either normoxia or chronic hypoxia for 14 d with or without CSE inhibitor L-PPG (50 mg/kg/d). (B) CSE protein
expression and disulfide PKGIα level in lungs of mice treated with CSE siRNA (1.3 mg·kg−1·d−1); RV pressure and RV to LV+S ratio in WT mice subjected to
either normoxia or chronic hypoxia for 14 d with or without CSE siRNA (1.3 mg·kg−1·d−1). (C) Disulfide PKGIα formation in response to persulfides donor K2Sx
treatment in human pulmonary artery smooth muscle cells. (D) RV pressure and RV to LV+septum ratio in C57BL/6 mice subjected to either normoxia or
chronic hypoxia for 14 d with or without persulfides donor K2Sx (2 mg·kg
−1·d−1); RV to LV+S ratio in WT or KI mice subjected to chronic hypoxia for 14 d with
or without K2Sx (2 mg·kg
−1·d−1). *P < 0.05, **P < 0.01 versus control; n = 5 to 7 per group. In some cases, the aspect ratio of the original immunoblots was
altered to enable a concise multipanel figure with a consistent presentation style; the original uncropped representative images of these immunoblots are
also available in SI Appendix, Fig. S10.
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Sustained pulmonary vasoconstriction is influenced by endothelial
release of vasoactive mediators and calcium, as well as by changes in
MLC phosphorylation (3). Protein kinase A (PKA) is another cyclic
nucleotide-dependent kinase that, like PKGIα, is also redox-
regulated by interprotein disulfide bond formation (69). PKA plays
a role in opposing vasoconstriction by phosphorylating targets that
reduce intracellular calcium concentration and promote relaxation
(1, 64). Redox-dead Cys17Ser PKARIα KI mice which cannot be
disulfide-activated (70) have increased aortic vascular reactivity to
vasopressor phenylephrine and deficient H2O2-dependent relaxation
(71). We subjected Cys17Ser PKARIα KI mice to chronic hypoxia,
but, in contrast to the Cys42Ser PKGIα KI, found no differences in
RV hypertrophy between the genotypes (SI Appendix, Fig. S7). These
observations are consistent with a specific adaptive role for disulfide
PKGIα in the lung in hypoxic PH scenario.
“Redox-Dead” Cys42Ser PKGIα KI Mice Develop Potentiated
Pulmonary EndoMT During Hypoxia-Induced PH. Smooth muscle
cell proliferation contributes to excessive muscularization of
pulmonary vessels during PH (2, 3). PKGI not only modulates
vasotone and the pressure within arteries but also continues to
emerge as an important player in cell differentiation, growth,
proliferation, and cancer progression (72–74). RV hypertro-
phic remodeling and pressure were assessed in WT and KI
mice subjected to hypoxia for 3 d, a time when pulmonary
disulfide PKGIα was elevated (Figs. 1A and 5A). WT mice
developed no RV hypertrophic remodeling at this time point,
and the RV pressure was similar to that in normoxic mice,
meaning that PH was reversible in the WT upon return to
normoxia—as occurs, for practical reasons, when RV pressure
is measured (Fig. 5A). Interestingly, the PKGI KI mice de-
veloped a larger increase in RV pressure and hypertrophy,
compared with the WTs, consistent with a more pronounced
and sustained pulmonary vasoconstriction—perhaps marking
the start of remodeling processes in the KI due to hypoxia. It
is likely that the disulfide PKGIα is crucial in the pulmonary
circulation even after 3 d of hypoxic exposure, by limiting
increases in PAP and RVSP, and this is likely why the KI mice
Fig. 4. “Redox-dead” Cys42Ser PKGIα KI mice subjected to chronic hypoxia develop potentiated PH. (A) RV to LV+S ratio, RV to BW ratio, atria weight to BW
ratio, and representative four-chamber view micrographs from hematoxylin eosin staining (H&E) stained heart sections, and (B) RVSP, RV end diastolic
pressure (RVEDP), and representative RV pressure tracings from WT or PKG KI mice subjected to either normoxia or chronic hypoxia for 28 d. (C) Changes in
pulmonary flow peak velocity, pulmonary acceleration time/pulmonary ejection time (PAT/ET), and estimated PVR in WT or KI mice subjected to either
normoxia or chronic hypoxia for 28 d. (D) Phosphorylated MLC (pMLC) and phosphorylated VASP (pVASP) protein expression in lungs from WT or KI mice
subjected to either normoxia or chronic hypoxia for 28 d. *P < 0.05, **P < 0.01, ***P < 0.001 versus control or respective WT; n = 12 to 14 per group, or, in
some experiments, n = 5 to 7 per group. In some cases, the aspect ratio of the original immunoblots was altered to enable a concise multipanel figure with a
consistent presentation style; the original uncropped representative images of these immunoblots are also available in SI Appendix, Fig. S10.











that cannot form the disulfide in PKGI develop a larger or
more sustained pressure increase.
Three days of hypoxia was therefore considered a logical time
point to monitor changes in gene expression, as this is before
structural remodeling in the WT had occurred, in an attempt to
define additional events that are important in the pathogenesis
of hypoxic pulmonary disease. Thus, a transcriptomic screen
using an Affymetrix microarray was performed on lungs from
WT or KI mice subjected to normoxia or hypoxia for 3 d.
Pathway analysis of these mRNA expression abundance data
Fig. 5. Enhanced pulmonary vascular growth signaling and EndoMT in redox-dead Cys42Ser PKGIα KI mice subjected to chronic hypoxia. (A) Pulmonary disulfide PKGIα
level in C57BL/6mice subjected to hypoxia for 1, 3, and 7 d; RVSP and RV to LV+S ratio fromWT or PKG KI mice subjected to short-time chronic hypoxia for 3 d. *P < 0.05,
**P < 0.001 versus control or WT; n = 6 to 8 per group. (B) Unbiased pathway analysis of processes with the largest number of alterations in gene expression in lungs of
WT or KI mice subjected to 3 d of hypoxia comparedwith normoxic animals, listed in descending order. (C) Representative confocal images in lung sections fromWT or KI
mice subjected to chronic hypoxia for 28 d, stained simultaneously with nuclear (DAPI, blue), smooth muscle (α-SMA, red), and endothelial (CD31, green) markers. (Scale
bar, 50 μm.) (D) Desmin, α-SMA, Twist-1, and phospho-vimentin protein expression in lungs from WT or KI mice subjected to chronic hypoxia for 28 d. *P < 0.05 versus
control; n = 6 to 8 per group. ECM, extracellular matrix; TGF, transforming growth factor; BMP, bone morphogenetic protein; JAK/STAT; janus kinase/signal transducer
and activator of transcription proteins; MAPK, mitogen-activated protein kinase; α-SMA, α-smooth muscle actin; CD31, cluster of differentiation 31; WT, wild type mice;
PKG KI, “redox-dead” Cys42Ser PKGIα KI mice. Unique effect is gene changes which are unique to either theWT or KI group. Common effects are gene changes that are
common to both theWT aswell as the KI group. Similar effects are gene changeswhich are neither common nor unique toWT or KI groups. This terminology reflects the
definitions in the Metalcore Training Manual (Version 5.0). In some cases, the aspect ratio of the original immunoblots was altered to enable a concise multipanel figure
with a consistent presentation style; the original uncropped representative images of these immunoblots are also available in SI Appendix, Fig. S11.
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revealed an up-regulation of progrowth, extracellular matrix
remodeling and endothelial-to-mesenchymal transition (EndoMT)
cellular signaling pathways in the KI compared with the WT after
3 d of hypoxia (Fig. 5B). This was notable, as EndoMT recently
emerged as an important regulator of pulmonary vascular remod-
eling in rodent models of PH and human disease (75).
Affymetrix microarray mRNA analysis was performed on the
whole lung; therefore, it was necessary to establish whether the
increased growth and EndoMT were evident in pulmonary blood
vessels. Increased coexpression of α-smooth muscle actin (α-SMA)
and cluster of differentiation 31 (CD31) in lung endothelial cells of
the KI mice subjected to hypoxia was prominent compared with
that measured in WT (Fig. 5C). Protein expressions of α-SMA and
desmin, as well as the EndoMT transcriptional regulator Twist-
1 and phosphorylated Vimentin (75) (Fig. 5D), were increased in
the lungs of the KI to a greater extent than those of WT following
hypoxia. The KI mice subjected to 28 d of hypoxia demonstrated
significantly exacerbated pulmonary vascular muscularization
compared with WT exposed to the same intervention, as evi-
denced by a greater accumulation of α-SMA expressing cells in
pulmonary vessels (SI Appendix, Fig. S6D). It is plausible that in-
creased disulfide PKGIα during hypoxia may prevent pulmonary
vascular muscularization, possibly by impairing EndoMT. Whether
this mechanism serves to alleviate pressure and PVR, perhaps
independently of the disulfide PKGIα pressure-lowering role, re-
mains to be definitively elucidated.
In summary, disulfide PKGIα accumulates during chronic
hypoxia in mouse and man, likely due to the accumulation of
H2O2, glutathione disulfide, and protein-bound persulfides
under these conditions. Depletion of superreducing persulfide
species in mouse hypoxic tissues may also contribute to
disulfide PKGIα abundance, which serves as an endogenous,
adaptive redox signaling mechanism that limits PH to atten-
uate RV hypertrophy and disease progression. Disulfide
PKGIα may also prevent the progression of EndoMT and so
limit adverse pulmonary vascular remodeling. Pharmacologi-
cal interventions that enhance disulfide PKGIα levels, such as
polysulfides as demonstrated herein, may provide a novel
therapeutic strategy to combat disease resulting from PH.
Materials and Methods
Animals, Induction of Hypoxic Pulmonary Hypertension, and Treatment. All
animal procedures were performed in accordance with the Home Office
Guidance on the Operation of the Animals (Scientific Procedures) Act 1986 in
the United Kingdom and were approved by the King’s College Animal
Welfare and Ethical Review Body. Mice constitutively expressing PKGIα
Cys42Ser were produced on a pure C57BL/6 background by Taconic Artemis
as described (8, 76) and bred on-site. Age- and body weight-matched WT or
PKGIα Cys42Ser KI male offspring were used in most of the studies. In some
experiments, age- and body weight-matched adult C57BL/6 male mice were
purchased from Charles River, as highlighted in more detail in Results and
Discussion. Animals had ad libitum access to standard chow and water and
were kept in specific pathogen-free conditions under a 12-h day/night cycle
at 20 °C and 60% humidity before hypoxic exposure. Hypoxic PH was in-
duced by exposing mice to normobaric hypoxia (10% of inspired O2) in a
large ventilated chamber (Biospherix, Ltd) (SI Appendix, Fig. S1). The CO2
level was monitored continuously with CO2 meter and soda lime. Fresh cage,
water, and food changes were performed once every 7 d to 10 d for all of
the animals. Additional materials and procedures can be found in SI Ap-
pendix, SI Materials and Methods.
Study Approval. All animal procedures were performed in accordance with
the Home Office Guidance on the Operation of the Animals (Scientific
Procedures) Act 1986 in the United Kingdomandwere approved by the King’s
College Animal Welfare and Ethical Review Body. The protocol of the study
using human samples was approved by the Ethics Committee of the Justus-
Liebig-University School of Medicine (No. 111/08 and 58/15). Informed con-
sent was obtained in written form from each subject.
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